Infinity Pharmaceuticals (INFIQ) 10-Q2018 Q1 Quarterly report

Filed: 8 May 18, 3:36pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: ACC, adapt, addressable, adrenocortical, agonist, amenable, Amsterdam, analyzed, antibody, apportioned, ASC, AstraZeneca, atezolizumab, avelumab, baseline, bill, bipartisan, blood, Brexit, British, broader, cabiralizumab, capable, carryover, Century, chamber, chemotherapy, composed, Conference, confusion, constraint, correlate, crowded, CSR, currency, customer, Cut, cyber, deducted, deduction, diagnosed, disadvantage, distinct, domain, durvalumab, Eisai, elderly, electorate, electrical, elotuzumab, EMA, epacadostat, EU, Europe, exhausted, explore, family, fashion, February, felt, field, flat, follicular, forecasted, formally, GCP, geopolitical, hedgehog, IDO, immigration, immunomodulatory, improve, Improvement, inadequacy, inappropriate, incidence, incident, incremental, indefinitely, inflation, IO, ipilimumab, Janssen, Johnson, kinase, Kingdom, labor, learned, leaving, Likewise, Lisbon, living, local, London, maker, mandate, marginal, mesothelioma, minimal, mix, Modernization, modernize, Morgan, move, neutrality, Notwithstanding, NSCLC, official, offshore, onsite, opportunity, paired, PellePharm, pembrolizumab, peripheral, peritoneal, permanently, pharmacodynamic, pharmacokinetic, PLC, political, pool, practical, practice, predominantly, predominate, prepayment, principle, proliferation, provisional, ratio, readily, regime, reinvigoration, repatriated, reproduce, resolved, routine, rulemaking, schema, single, skinny, slated, spur, sublicensed, subset, subsidiary, suggesting, suppressor, Surface, Syndax, taxation, telecommunication, territory, terrorism, threshold, TME, Treaty, tremelimumab, UK, unclear, undergone, undermine, unrest, upregulation, urelumab, urge, vulnerability, vulnerable, war

Removed: AACR, account, attain, bearing, BHX, building, Center, commensurate, component, construction, contemplated, controlled, culminating, dated, deferral, deferred, deliverable, delivered, delivery, deposit, discrete, divest, DYNAMO, electronically, element, endpoint, enhancement, ESPP, estimable, exercising, explain, expressed, furniture, headcount, highest, implanted, indolent, infused, inhaled, iNHL, initiate, initiated, injected, instilled, IPAB, irrevocable, landlord, letter, life, lowering, network, Nonretirement, offsetting, Opdivo, original, outline, outlined, outpatient, owner, PD, perpetual, phenotype, PK, Postemployment, precisely, preserve, proportional, proportionate, Realty, receivable, recommend, reflecting, refund, release, reprogramming, retained, separated, shared, specific, stored, structural, suit, suspended, tampering, temporarily, theft, Trust, trustee, twenty, undertook, unilaterally, unit

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated INFIQ transcripts

INFIQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

STATEMENT PURSUANT TO 18 U.S.C. §1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. §1350, the undersigned certifies that, to his knowledge, this Quarterly Report on Form 10-Q for the period ended March 31, 2018 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Infinity Pharmaceuticals, Inc.



Date: May 8, 2018		/s/Lawrence E. Bloch, M.D., J.D.
		Lawrence E. Bloch, M.D., J.D.
		President
		(Principal Financial Officer & Principal Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to Infinity Pharmaceuticals, Inc. and will be retained by Infinity Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.